Trials / Terminated
TerminatedNCT01876251
A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
Phase 1b Study Of Docetaxel + Pf 03084014 In Metastatic Or Locally Recurrent/Advanced Triple Negative Breast Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is aimed to determine the tolerability of the PF-03084014 plus docetaxel combination in patients with advanced breast cancer. Preliminary information about the efficacy of the combination will also be collected.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-03084014 | Tablet, 10 mg, twice a day |
| DRUG | PF-03084014 | Tablet, 50 mg, twice a day |
| DRUG | PF-03084014 | Tablet, 100 mg, twice a day |
| DRUG | Docetaxel | Solution for IV infusion 75 mg/m\^2, every 3 weeks |
| DRUG | Docetaxel | Solution for IV infusion 100 mg/m\^2, every 3 weeks |
Timeline
- Start date
- 2013-11-04
- Primary completion
- 2015-12-24
- Completion
- 2015-12-24
- First posted
- 2013-06-12
- Last updated
- 2019-03-15
- Results posted
- 2019-03-15
Locations
16 sites across 4 countries: United States, Belgium, Italy, Spain
Source: ClinicalTrials.gov record NCT01876251. Inclusion in this directory is not an endorsement.